Knight Therapeutics (TSE:GUD) Sets New 52-Week High – What’s Next?

Shares of Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Friday. The stock traded as high as C$11.09 and last traded at C$11.04, with a volume of 48,763 shares traded. The stock had previously closed at C$10.80.

Knight Therapeutics Stock Up 2.9%

The company has a quick ratio of 1.79, a current ratio of 2.28 and a debt-to-equity ratio of 4.29. The firm has a 50 day moving average of C$10.03 and a two-hundred day moving average of C$9.19. The firm has a market capitalization of C$1.09 billion, a price-to-earnings ratio of 74.07, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.45.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. The business had revenue of C$143.97 million for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%. As a group, sell-side analysts anticipate that Knight Therapeutics Inc. will post 0.10 EPS for the current fiscal year.

About Knight Therapeutics

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.